Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867875 | 1.00 | ARG1 (0.58) | ARG1ALDH1A1S1PR3CYP1A2ALOX15 | |
| SCHEMBL5511790 | 0.95 | ARG1 (0.60) | ARG1ALDH1A1S1PR3CYP1A2ALOX15 | |
| SCHEMBL3787271 | 0.95 | ARG1 (0.60) | ARG1ALDH1A1S1PR3CYP1A2ALOX15 | |
| SCHEMBL26118062 | 0.87 | ARG1 (0.64) | ARG1ALDH1A1CYP1A2ALOX15CYP2C19 | |
| SCHEMBL11650754 | 0.87 | ARG1 (0.64) | ARG1ALDH1A1CYP1A2ALOX15CYP2C19 | |
| SCHEMBL1034091 | 0.87 | ARG1 (0.64) | ARG1ALDH1A1CYP1A2ALOX15CYP2C19 | |
| SCHEMBL3776510 | 0.87 | ARG1 (0.64) | ARG1ALDH1A1CYP1A2ALOX15CYP2C19 | |
| SCHEMBL10076629 | 0.85 | DRD3 (0.43) | ARG1ALDH1A1S1PR3DRD3SLC6A3 | |
| SCHEMBL1567292 | 0.83 | ARG1 (0.60) | ARG1ALDH1A1S1PR3CYP1A2ALOX15 | |
| SCHEMBL28637907 | 0.82 | DRD3 (0.60) | ARG1ALDH1A1S1PR3CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010541-B2 | Modulation of tissue transglutaminase activation in disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160339012-A1 | Modulation of Tissue Transglutaminase Activation in Disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2015116846-A1 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2010127645-A2 | THE METHOD OF BIOTECHNOLOGICAL PREPARATION OF LINCOMYCIN DERIVATIVES AND ITS USING | INSTITUTE OF MICROBIOLOGY AS CR, V. V. I. (CZ) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010541-B2 | Modulation of tissue transglutaminase activation in disease | TGM2, GLS, TGM3 | ARG1 240/4885ALDH1A1 3710/4885S1PR3 2956/4885 |
| US-20160339012-A1 | Modulation of Tissue Transglutaminase Activation in Disease | TGM2, GLS, TGM3 | ARG1 240/4885ALDH1A1 3710/4885S1PR3 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.